- (4) at least five contiguous nucleotides nonidentical to the sequence group,
- (5) at least six contiguous nucleotides nonidentical to the sequence group, and
- (6) at least seven contiguous nucleotides nonideratical to the sequence group.

80. (new) The isolated nucleic acid molecule of claim 4/wherein the unique fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12, nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20 nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28, nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides and 200 nucleotides.

- 81. (new) The isolated nucleic acid molecule of claim 4, wherein the molecule encodes a polypeptide which is immunogenic.
- 82. (new) An expression vector comprising the isolated nucleic acid molecule of claim 2 operably linked to a promoter.
- 83. (new) An expression vector comprising the isolated nucleic acid molecule of claim 3 operably linked to a promoter.
- 84. (new) An expression vector comprising the isolated nucleic acid molecule of claim 4 operably linked to a promoter.
- 85. (new) An expression vector comprising the isolated nucleic acid molecule of claim 79 operably linked to a promoter.
- 86. (new) An expression vector comprising the isolated nucleic acid molecule of claim 80 operably linked to a promoter.
- 87. (new) An expression vector comprising the isolated nucleic acid molecule of claim 81 operably linked to a promoter.

Sub-